Hydrogenation of curcumin (1), a chemopreventive agent from Turmeric (Curcuma longa L.) yielded three major compounds: 1,7-bis(4-hydroxy-3methoxyphenyl)heptane-3,5-dione (2), 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3-one (3), and 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol (4). Incubation of compound (2) with Beauveria bassiana ATCC 7159 afforded the hexahydrocurcumin (3) as the sole metabolite while biotransformation of curcumin (1) with B. bassiana gave metabolites 2-4 along with the curcumin-4ʹ-O-4ʹʹʹ-O-methyl-β-D-glucopyranoside (5) and octahydrocurcumin-4ʹ-O-4ʹʹʹ-O-methyl-β-D-glucopyranoside (6). The bioconversion of curcumin (1) with Rhizopus oryzae ATCC 11145 yielded analogs 2-4 while no transformation of curcumin (1) was observed with Aspergillus niger ATCC 16888. The preparation, structural elucidation and biological activities of these metabolites are reported herein.
Curcumin (1) is the main polyphenolic constituent of the spice Tumeric (Curcuma longa L. rhizomes) [1] . It was first isolated in 1815 and its structure was determined in 1910 [2] . The yellow spice has been used for over 6000 years for medicinal reasons in Indian and other Asian cultures.
It possesses a wide range of pharmacological activities [3a-3c] such as anti-inflammatory [4] , antioxidant [5a,5b,6] , Antiarthritic [7a] , wound healing [7b], antimicrobial effects [7c], and cancer chemopreventive activities [2,7d,8] . The underlying basis of these effects is attributed to its regulation on several molecular targets including: transcription factors, growth regulators, protein kinases, inflammatory cytokines, adhesion molecules, apoptotic genes, angiogenesis regulators, and cellular signaling molecules [2] . As a result of these impressive bioactivity profiles, curcumin (1) has been the subject of considerable interest by researchers.
The metabolism of curcumin (1) in rodents and humans affords metabolites undergoing either reduction or conjugation. Curcumin (1), when administered intraperitoneally or systemically, is reduced to the tetrahydrocurcumin (THC) (2) , hexahydrocurcumin (HHC) (3) and octahydrocurcumin (OHC) (4) whilst oral administration of curcumin (1) yields curcuminglucuronide and sulphates [5a,9,10a-10c] . The transformation of curcumin (1) by microorganisms have also resulted in production of glucosides [11a,11b] and reduced metabolites [8,11c] . Bioassay data has shown that the THC (2) and HHC (3) metabolites, for example, exhibit better antioxidant properties than curcumin (1) [5a,12a,12b] .
Despite its significant biological profile, curcumin (1) still suffers from poor bioavailability which is crucial for its clinical success. The generation of curcumin glycosides [11a,11b] and curcumin (1) encapsulated in nanoparticles [12c] represent different approaches to address this shortfall. More effort, however, is still needed to successfully address this problem. In our ongoing program to increase the bioavailability and the number of potentially bioactive analogs of curcumin (1), the modification of curcumin (1) was conducted via synthetic and microbial means. The report herein describes the preparation, structural elucidation, and biological activities of curcumin analogs.
In an attempt to generate potentially new analogs of curcumin (1) for fungal bioconversion the hydrogenation of curcumin (1) in methanol and in acetone were first evaluated separately. Reduction using acetone as solvent afforded fewer major products than in methanol so this approach was used as the preferred method moving forward. Hydrogenation of curcumin (1) in acetone yielded three major compounds [13, 14] . Purification on silica gel with increasing concentration of ethyl acetate in hexane afforded analogs 2-4. LRMS of compound 2 gave a MW of 372 atomic mass units (amu). This implied an increase of four amu (the addition of four hydrogens) when compared to curcumin (1) . Comparison of the 1 H and 13 C NMR data of 2 with those in literature suggested that it was the known 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (2) [14, 15] . Likewise, analog 3 displayed a mass of m/z = 376 and its 1 H and 13 C NMR data matched those in literature for 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3-one (3). Analog 4 was confirmed as 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5diol (4) based on comparable physical (m/z = 378) and spectroscopic data with those in literature [14, 15] . With the identification of the analogs 2-4 in hand we attempted to investigate the biotransformation potential of the least nonpolar analog 2 since it was the least modified curcuminoid. Utilizing the prolific microbial transformer Beauveria bassiana [16] , the incubation of the tetrahydrocurcumin (THC) analog 2 was carried out and this surprisingly afforded only one metabolite. LRMS of this metabolite suggested an increase in the atomic mass units by two (m/z = 374) when compared to analog 2. Analysis of the 1 H and 13 C NMR data revealed the reduction of one of the carbonyl groups to yield the hexahydrocurcumin (HHC) analog 3 [17a] . This result represents the first reported microbial transformation of analog 2 to yield a single metabolite 3. Having obtained the resultant product 3 as the sole metabolite from the bioconversion of 2 with B. bassiana, a comparative study of synthetic versus microbial modification of the parent congener curcumin (1) was conducted to determine the range of potential metabolites that could be realized. Curcumin (1) was therefore incubated with the well-known microbial transformers Beauveria bassiana [16] , Aspergillus niger [17b], and Rhizopus oryzae [18] .
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Incubation of curcumin (1) with A. niger resulted only in the untransformed starting material while microbial transformation of curcumin (1) with R. oryzae afforded aforementioned metabolites 2-4, with metabolite 2 as the major compound (Table 1) . Compounds 2-4 were confirmed as before via MS and NMR data. The fungus mainly modified the parent chain and without affecting the polyphenyl groups.
This represents the first reported bioconversion of curcumin (1) by R. oryzae. A different result was described in the bioconversion of curcumin (1) with another Rhizopus species (R. chinensis) [11a] . Transformation of curcumin (1) afforded only the curcumin-4′-O-β-D-glucoside and the hexahydrocumin products. No glycoside was observed in our work. This difference in the outcome could be due to different cytochrome P-450 enzymes between the Rhizopus species.
Fungal bioconversion of curcumin (1) by B. bassiana yielded five metabolites based on comparative TLC analyses with the control. The metabolites were separated on silica gel column with increasing concentration of ethyl acetate in hexane. The least polar metabolite that was eluted in 20% ethyl acetate in hexane revealed a mass of m/z = 372 from LCMS data. This increase by four amu suggested reduction of either two olefinic or carbonyl moieties. 1 H and 13 C NMR data confirmed the reduction of two olefinic groups hence the metabolite was confirmed the THC (2) ( Table 1) .
Elution in 25% ethyl acetate in hexane resulted in the untransformed curcumin (1) . Elution in 30% ethyl acetate in hexane afforded the second and third metabolites that exhibited masses of m/z 374 and 376 respectively from LRMS data. IR, 1 H and 13 C NMR data confirmed them as HHC (3) and OHC (4). 13 C NMR data revealed the presence of the aforementioned 4'-O-methyl-glucose moiety with five additional methine carbon (CH), one methylene carbon (CH 2 ) and one methoxy (OCH 3 ) resonances. This metabolite was therefore determined to be the octahydrocurcumin-4'-O-4'''-Omethyl-β-D-glucopyranoside (6) based on the difference in mass from the sugar unit. Metabolite 6 is the first reported glycoside from the fermentation of curcumin (1) with B. bassiana. In order to determine the bioactive potential of curcumin (1) and its analogs (2-4) they were examined in a series of chemopreventive bioassays ( Table 2 ). They were evaluated for their potential to induce Quinone reductase 1 (QR1), interact with retinoid X receptors (RXRE), inhibit aromatase, tumor necrosis factor-α induced NFB, and nitric oxide (NO) production. The hexahydrocurcumin (3) was the most effective metabolite across the bioassays tested. All the compounds exhibited single fold induction in the retinoid X receptor (RXRE) assay. Curcumin (1) demonstrated moderate activities in the aromatase (IC 50 = 31.4 µM) and Quinone reductase 1 (IC 50 = 9.5 µM) assays and weak activity in NFκB (exhibited 47% inhibition at the 20 µg/mL test concentration). No significant activity was noted in the nitric oxide (NO) production assay at the 20 µg/mL test concentration. Similar activity profiles were also noted for the octahydrocurcumin (4) in the aromatase (IC 50 = 49.9 µM) and NFκB (exhibited 40% inhibition at the 20 µg/mL test concentration) assays along with moderate (IC 50 = 45.6 µM) and no significant activity (NSA) in the NO and QR1 assays respectively. The tetrahydrocurcumin (2) displayed moderate activities in both the NFκB (IC 50 = 32.8 µM) and NO (IC 50 = 46.5 µM) assays with weak activity in the aromatase assay (exhibited 40% inhibition at the 20 µg/mL test concentration). No significant activity was observed in the QR1 assay.
In summary, we developed an alternative microbial method for the production of curcumin (1) derivatives utilizing more green chemistry conditions. Curcumin (1) was successfully biotransformed to its reduced metabolites 2-4 and glucopyranosides 5-6. The bio-reduced metabolites 2-4 were the same as those obtained by chemical means. Metabolites 2-4 displayed weak to moderate biological activities in the chemopreventive bioassays. The bioconversion of the tetrahydrocurcumin (THC) (2) to the hexahydrocurcumin (HHC) (3) as the sole metabolite is reported for the first time and metabolite 6 is a second glycoside from the fermentation of curcumin (1) with B. bassiana.
Experimental
General: Melting points, Mel-Temp II capillary melting point apparatus; IR, Perkin-Elmer FT-IR spectrophotometer; UV, Perkin Elmer Lambda UV/VIS spectrometer; NMR, Bruker VNMR-600 NMR; LRMS, Thermo Scientific TSQ Quantum™ Access MAX Triple Quadrupole Mass Spectrometer; HRMS, Agilent 6210 TOF-MS; CC, silica gel (37-63 µm diameter); Detection of compounds on thin layer chromatography (TLC) was achieved by spraying the
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Natural Product Communications Vol. 12 (4) 2017 561 plates with phosphomolybdic acid solution followed by heating until the color developed. Aspergillus niger ATCC 16888, Beauveria bassiana ATCC 7159 and Rhizopus oryzae ATCC 11145 were obtained from the American Type Culture Collection (ATCC), Rockville, MD, USA.
Culture conditions:
Aspergillus niger ATCC 16888 and Beauveria bassiana ATCC 7159 were maintained on potato dextrose agar slants and Rhizopus oryzae ATCC 11145 on sabouraud dextrose agar slants at 25 °C for two weeks. For each fungus, 10 slants (4 days old) were used to inoculate ten 500 ml Erlenmeyer flasks, each containing 250 ml liquid culture medium. The liquid medium (2.5 L) for R. oryzae contained glucose (20 g/L), yeast extract (5 g/L), sodium chloride (5 g/L), and dipotassium hydrogen phosphate (5 g/L) while the liquid medium (2.5 L) for A. niger and B. bassiana compromised of potato dextrose broth. The flasks were shaken at 80 rpm at 27°C. The substrate (0.5 -1 g) was pulse fed to the growing fungus (10 flasks) in portions of 10, 20, 30 and 40% at 24, 36, 48 and 60 h after inoculation. The fermentation proceeded for 5 days.
Reduction of curcumin (1):
To curcumin (1) (3 g) dissolved in acetone (50 mL) was added 10% Pd/C (0.3 g). The reaction mixture was hydrogenated at 60 psi overnight. The mixture was filtered under vacuum and the filtrate was concentrated in vacuo to provide a crude extract (2.9 g). Purification on silica gel with 20 -35% ethyl acetate in hexane afforded the bis(4-hydroxyphenyl)heptane-3,5-dione (2) (1.3 g), 1,7-bis(4-hydroxy-3-methoxyphenyl)-5-hydroxy-3-heptanone (3) (0.5 g), and 1,7-bis(4-hydroxy-3methoxyphenyl)-3,5-heptanediol (4) (0.9 g). Identification of these compounds was confirmed based on comparison of their 1 H and 13 C NMR and mass spectral data with those reported in the literature.
Bioconversion of 1,7-bis(4-hydroxyphenyl)-heptane-3,5-dione (2) with B. bassiana:
The compound 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione (2) (500 mg) was pulse fed to the B. bassiana (10 flasks/compound) in portions of 10, 20, 30 and 40% at 24, 36, 48 and 60 h after inoculation. The fermentation was allowed to proceed for 5 days. The fungal mycelium was filtered from the broth and the broth was extracted with ethyl acetate (2 X 600 ml). The fungal cells were homogenized and extracted in warm ethyl acetate (500 ml). The organic solutions were dried with anhydrous sodium sulfate, filtered, concentrated in vacuo and analyzed by thin layer chromatography (TLC). The crude extracts were combined and purified on silica gel with increasing concentrations of ethyl acetate in hexane. Elution in 25% ethyl acetate in hexane yielded the untransformed tetrahydrocurcumin (2, 38 mg). Further elution in 30% ethyl acetate in hexane afforded the hexahydrocurcumin (3, 215 mg) as the sole metabolite.
Bioconversion of curcumin (1) with B. bassiana:
The bioconversion of curcumin (1) (1 g) with B. bassiana provided mycelial and broth extracts that were combined and chromatographed on silica gel. Elution in 20% ethyl acetate in hexane yielded the tetrahydrocurcumin 2 (16 mg) while elution in 25% ethyl acetate in hexane afforded the untransformed curcumin (1) . The metabolite hexahydrocurcumin analog 3 (370 mg) was obtained in 30% ethyl acetate in hexane and elution in 50% ethyl acetate in hexane provided octahydrocurcumin (4) (220 mg). Curcumin-4ʹ-O-4ʹʹʹ-O-methyl-β-D-glucopyranoside (5) (58 mg) and octahydrocurcumin-4ʹ-O-4ʹʹʹ-O-methyl-β-D-glucopyranoside (6) (140 mg) were eluted in 70% ethyl acetate in hexane.
Bioconversion of curcumin (1) with R. oryzae:
Curcumin (1) (1 g) was pulse fed to R. oryzae. Workup yielded broth and mycelial extracts that were pooled and purified on silica gel. Elution in 25% ethyl acetate in hexane afforded 1,7-bis(4-hydroxy-3methoxyphenyl)heptane-3,5-dione (2) (55 mg). The untransformed curcumin (1) was eluted in 25% ethyl acetate in hexane. Elution in 30% ethyl acetate in hexane gave the metabolite 5-hydroxy-1,7bis(4-hydroxy-3-methoxyphenyl)heptan-3-one (3) (35 mg) and elution in 50% ethyl acetate in hexane afforded 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol (4) (11 mg).
Bioconversion of curcumin (1) with A. niger:
Curcumin (1) (1 g) was pulse fed to A. niger. Workup yielded broth and mycelial extracts which were pooled and purified on silica gel. Elution in 25% ethyl acetate in hexane only afforded the untransformed curcumin (1) .
NFκB Luciferase Assay:
Human embryonic kidney cells 293, purchased from Panomics Inc. (Fremont, CA), were utilized in monitoring changes along the NFκB pathway. The treated cells were lysed using Reporter Lysis buffer after incubation. The luciferase enzyme (gene product) reacts with the luciferase substrate by emitting light and this is detected with a luminometer. The luciferase assay was conducted in accordance with the Luc assay system from Promega [19] . The data collected were expressed as % inhibition or IC 50 values (i.e., concentration of test sample required to inhibit TNF-α activated NFκB activity by 50%). Nα-tosyl-Lphenylalanine chloromethyl ketone (TPCK) was used as a positive control in this assay; IC 50 = 5.09 µM. Test samples 1 and 2-4 were evaluated for aromatase inhibition according to a previously reported protocol [20] . The test sample was pre-incubated with a NADPH regenerating system at 37°C. The aromatase enzyme and substrate mixture were added and the plate was allowed to incubate for 30 min before it was quenched with 2N NaOH. Fluorescence was measured at 485 nm (excitation) and 530 nm (emission).
Aromatase assay:

Quinone reductase 1 (QR1) assay:
Hepa 1c1c7 murine hepatoma cells were used to measure QR1 activity as formerly described [21] . The cells were incubated in a 96-well plate with samples .at a maximum concentration of 20 μg/mL. The QR activity was obtained by measuring the NADPH-dependent menadiol-mediated reduction of 3-(4,5-dimetylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a blue formazan. Induction of QR activity was determined by comparing the QR specific activity of agent-treated cells with that of solvent control, and CDs were produced. CD is the concentration required to double QR induction.
The chemopreventive index (CI) is determined as a ratio of IC 50 to CD. The 4′-Bromoflavone (CD = 0.01 μM) compound was used as the positive control.
Nitric oxide (NO) synthase assay:
The NO synthase assay was conducted as reported earlier [19] . RAW 264.7 cells (1 × 10 5 cells/well) were incubated in a 96-well culture plate for 24 h. The cells were treated with serially diluted test samples dissolved in phenol red-free DMEM for 30 min followed by 1 g/ml of LPS treatment for 24 h. The unstable NO was oxidized to stable nitrite end product. NO production was estimated (via nitrite release) with the addition of Griess reagent [1:1 mixture (v/v) of 1% sulfanilamide and 0.1% N-(1-naphthyl)ethylenediamine in 2.5% H 3 PO 4 ] and absorbance was measured at 540 nm. A standard curve was established with known concentrations of sodium nitrite.
Retinoid X Receptor Responsive Element (RXRE)-Luciferase reporter gene assay:
This assay was carried out as described beforehand [22] . COS-1 cells were plated and incubated for 24 h. The Lipofctamine TM 2000 transfection reagent was used to transfect the cells with Renilla reniformis luciferase vector (pRL-SV40), RXR responsive element encoding vector (pRXRE), and human RXRα protein expressing vector (phRXRα). The cells were treated with the test samples after 24 h of transfection and were further incubated for another 24 h. The cells were lysed and a dual luciferase assay was carried out. The results were presented as a relative value calculated by fold increase over control after normalizing ratios of firefly luciferase/Renilla luciferase. 9-Cisretinoic acid was used as a positive control and the cut-off was set at 4-fold induction.
